Abstract 2077P
Background
To investigate the efficacy of Superoxide Dismutase (SOD, 70 UI), Palmitoyethanolamide (PEA, 300 mg) Alpha Lipoic Acid (ALA, 300 mg),vitamins B6 (1.5 mg), B1 (1.1 mg), B12(2.5 mcg), E (7.5 mg), Nicotinamide (9 mg) and minerals (Mg 30 mg, Zn 2,5 mg) in one tablet in managing neuropathic pain due to cancer chemotherapy.
Methods
In this pilot study, 67 age-matched patients with cancer (41 men) and a mean age of 65.4 years were randomly assigned, either to receive the combination of ten elements (2 tablets/24h) in the active A group, (n=33), or the placebo B (n=34) for six months. Nerve function was assessed by DPN Check [sural nerve conduction velocity (SNCV) and amplitude (SNAP)]. Sudomotor function was evaluated with SUDOSCAN, which measures electRochemical skin conductance in hands and feet (ESCH and ESCF). We used Pain questionnaires: Pain Detect (PD), Neuropathic Pain Symptom Inventory (NPSI), and Visual Analog Scale (VAS) for the estimation of neuropathic pain, also. All patients received Taxanes and platinum analogs as cancer chemotherapy.
Results
At follow-up, measurements from SNCV, SNAP, ESCH and ESCF did not change significantly in both groups. In A group PD baseline vs. final (9.57±7.0 vs. 6.78±4.16, p=0.003), NPSI (28.51±21.26 vs. 19.87±12.6, p<0.001) and VAS (27.78±22.40 vs 21.48±17.79, p=0.003) improved significantly during follow up. In group B PD (7.03±5.19 vs. 9.71±6.61 p<0.001), NPSI (23.50±18.99 vs. 36.25±22.15, p<0.001), and VAS (25.03±23.83 vs 38.75±26.60 p<0.001) deteriorated. No side effects detected.
Conclusions
The combination of the ten elements as supplement in one tablet for six months at a daily dose of two pills in patients improved neuropathic pain due to cancer chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06